文献速递皮肤肿瘤

高风险原发性黑色素瘤诊断后复发风险研究

Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor.
PubMed 文献 · JAMA Dermatol · 2019-01-01

该前瞻性队列研究纳入澳大利亚昆士兰700例新诊断的T1b至T4b期局限性黑色素瘤患者,分析复发风险。结果显示13.4%的患者在诊断后2年内复发,其中70.2%为局部区域复发,29.8%为远处转移。原发肿瘤位于头颈部、溃疡、厚度及核分裂率>3/mm2是复发的独立预测因素。

要点

  • 高风险原发性黑色素瘤患者2年内复发率为13.4%。
  • 头颈部原发肿瘤、溃疡、厚度及核分裂率>3/mm2与复发独立相关(HR 2.36)。
  • 未行前哨淋巴结活检的T2a-T4a患者无病生存率低于活检阴性者。

核心结论

  • 13.4%的高风险原发性黑色素瘤患者在诊断后2年内出现复发。
  • 原发肿瘤位于头颈部、前哨淋巴结活检阳性及肿瘤快速生长迹象可能与复发相关。

研究设计与样本

  • 前瞻性队列研究,2010年10月1日至2014年10月1日在澳大利亚昆士兰招募1254例新诊断、组织学确诊的T1b至T4b期黑色素瘤患者,最终700例纳入分析。
  • 使用Cox比例风险回归分析患者及肿瘤因素与黑色素瘤复发的关联。

主要发现

  • 局部区域疾病手术后,64例中37例(57.8%)在2年时保持无病,7例(10.9%)出现新的局部区域复发,20例(31.3%)出现远处疾病。
  • 独立预测因素包括原发肿瘤位于头颈部、溃疡、厚度及核分裂率>3/mm2(HR 2.36;95% CI 1.19-4.71)。
  • AJCC第7版与第8版分期在T1b和T4b类别中2年无病生存率相似:T1b AJCC 7为253例(93.3% DFS),AJCC 8为242例(93.0% DFS);T4b两版均为50例(68.0% DFS)。
  • 未行前哨淋巴结活检的T2a至T4a患者无病生存率低于同类别且活检阴性者:T2a未活检136例(91.1%;95% CI 86.4-95.9)vs 活检阴性96例(96.9%;95% CI 93.4-100.0);T4a未活检33例(78.8%;95% CI 64.8-92.7)vs 活检阴性6例(83.3%;95% CI 53.5-100.0)。

关键数值与推荐

  • 高风险原发性黑色素瘤定义为AJCC第8版T1b至T4b期。
  • 复发通过每6个月随访问卷自报,并经组织学或影像学确认。
  • 核分裂率>3/mm2的复发风险比(HR)为2.36(95% CI 1.19-4.71)。

临床怎么用

  • 对高风险原发性黑色素瘤患者应加强前2年的复发监测。
  • 考虑对T2a至T4a患者进行前哨淋巴结活检以改善风险分层。
  • 头颈部原发、溃疡、厚度及高核分裂率患者需更密切随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: With emerging new systemic treatments for metastatic melanoma, early detection of disease recurrence is increasingly important. OBJECTIVE: To investigate the risk of melanoma recurrence in patients with a localized melanoma at a high risk of metastasis. DESIGN, SETTING, AND PARTICIPANTS: A total of 1254 patients with newly diagnosed, histologically confirmed tumor category T1b to T4b melanoma in Queensland, Australia, were recruited prospectively between October 1, 2010, and October 1, 2014, for participation in a cohort study. Data analysis was conducted from February 8, 2018, to February 20, 2019. We used Cox proportional hazards regression analysis to examine associations between patient and tumor factors and melanoma recurrence. EXPOSURES: Disease-free survival (DFS) by melanoma tumor category defined by the 7th vs 8th editions of the AJCC Cancer Staging Manual (AJCC 7 vs AJCC 8). MAIN OUTCOMES AND MEASURES: Melanoma recurrences were self-reported through follow-up questionnaires administered every 6 months and confirmed by histologic or imaging findings. RESULTS: Of 1254 patients recruited, 825 individuals (65.8%) agreed to participate. Thirty-six were found to be ineligible after providing consent and a further 89 patients were excluded after reclassifying tumors using AJCC 8, leaving 700 participants with high-risk primary melanoma (mean [SD] age, 62.2 [13.5] years; 410 [58.6%] men). Independent predictors of recurrence were head or neck site of primary tumor, ulceration, thickness, and mitotic rate greater than 3/mm2 (hazard ratio, 2.36; 95% CI, 1.19-4.71). Ninety-four patients (13.4%) developed a recurrence within 2 years of diagnosis: 66 tumors (70.2%) were locoregional, and 28 tumors (29.8%) developed at distant sites. After surgery for locoregional disease, 37 of 64 patients (57.8%) remained disease free at 2 years, 7 patients (10.9%) developed new locoregional recurrence, and 20 patients (31.3%), developed distant disease. Two-year DFS was similar when comparing AJCC 7 and AJCC 8, for T1b (AJCC 7, 253 [93.3% DFS]; AJCC 8, 242 [93.0% DFS]) and T4b (AJCC 7 and AJCC 8, 50 [68.0% DFS] category tumors in both editions. Patients with T2a to T4a tumors who did not have a sentinel lymph node biopsy (SLNB) at diagnosis had lower DFS than patients with the same tumor category and a negative SLNB (T2a: 136 [91.1%; 95% CI, 86.4-95.9] vs 96 [96.9%; 95 % CI, 93.4-100.0]; T4a: 33 [78.8%; 95% CI, 64.8-92.7] vs 6 [83.3; 95% CI, 53.5-100.0]). CONCLUSIONS AND RELEVANCE: These findings suggest that 13.4% of patients with a high-risk primary melanoma will experience disease recurrence within 2 years. Head or neck location of initial tumor, SLNB positivity, and signs of rapid tumor growth may be associated with primary melanoma recurrence.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. von Schuckmann LA, Hughes MCB, Ghiasvand R, et al. Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor. JAMA Dermatol. 2019. PMID: 31042258. doi:10.1001/jamadermatol.2019.0440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。